Vanda Pharmaceuticals announced its participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, presenting new data on imsidolimab, a monoclonal antibody in development for generalized pustular psoriasis (GPP), a rare skin condition. The presentations highlighted imsidolimab's rapid effect on reducing neutrophils and improving pustulation symptoms, based on results from the GEMINI-1 study. Vanda holds exclusive global rights to develop and commercialize imsidolimab, with regulatory and patent protections expected into the late 2030s. This progress underscores Vanda's commitment to innovative treatments for unmet medical needs and may impact future psoriasis therapies.
Vanda Pharmaceuticals' presentation at the 2026 EADV Annual Meeting comes as 78 out of 100 health-sector US stocks tradable on Pluang rose today. For readers following the health sector, here is Pluang's market snapshot as of Oct 02, 2026 19:52 WIB: TLRY (Tilray Brands Inc) traded at USD 3.64 with a 1-day change of +1.96% and a typical hold time of 30 days, FLNA (Cassava Sciences Inc) at USD 0.95 with a -1.96% change and 37 days hold time, and BNGO (BioNano Genomics Inc) at USD 1.60 with a +1.91% change and 49 days hold time. Pluang order activity varied, showing mixed buy and sell interest across these stocks.
Scotiabank has lowered its price target for Comcast from $29.00 to $27.50 as the stock faces significant challenges, including a 12-year low trading price and increased competition from services like Starlink. Comcast's share price has dropped 58% si...
UBS has maintained its Buy rating on PepsiCo but lowered the price target from $159 to $145 following a nearly 8% drop in PepsiCo's stock over the past month. Investors are awaiting the company's Q3 earnings report on October 8, with analysts expecti...
UBS has maintained a Neutral rating on Nike stock following the company's fiscal first-quarter revenue falling short of estimates and its announcement of layoffs. Nike's shares dropped over 7% amid weak earnings guidance and expectations of further s...
Acuity Inc. reported strong fiscal Q4 earnings with adjusted EPS of $5.77, beating analyst estimates despite net sales of $1.244 billion falling just short of consensus. Operating profit rose 25.7% to $227 million, and operating margin expanded to 18...
Analysts from Robert W. Baird and Bank of America have lowered their price targets for Fair Isaac (FICO) due to changes in mortgage rules by Fannie Mae and Freddie Mac. These changes favor alternative credit scoring models like VantageScore, potentia...
